Peanut Allergy

99 registered clinical trials studyying Peanut Allergy — 10 currently recruiting.

Status	Trial	Sponsor	Phase
Not Yet Recruiting	Comparing Standard and Autoclaved Peanut Oral Immunotherapy in People With Peanut Allergy NCT07439406	McGill University Health Centre/Research Institute of the McGill University Health Centre	Phase 2
Recruiting	UKK-0018 as an Immunotherapeutic for Treatment of Peanut Allergies NCT07349212	Ukko Inc	Phase 1 / Phase 2
Not Yet Recruiting	Efficacy of Tezepelumab in Peanut Oral Immunotherapy NCT07015996	National Institute of Allergy and Infectious Diseases (NIAID)	Phase 2
Not Yet Recruiting	Study of ENP-501 in Peanut-Allergic and Non-Allergic Participants NCT07117669	N-Fold, LLC	Phase 1 / Phase 2
Recruiting	Safety Study of Viaskin® Peanut Patch in Peanut-Allergic Children 1 Through 3 Years of Age (COMFORT Toddlers) NCT07003919	DBV Technologies	Phase 3
Completed	Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of IGNX001 NCT06331728	IgGenix Australia Pty Ltd	Phase 1
Withdrawn	Analysing HIgh Dose Probiotic Peanut Oral Immunotherapy (PPOIT) and High Dose Peanut Oral Immunotherapy (OIT) NCT06297083	Murdoch Childrens Research Institute	Phase 2
Recruiting	Evaluating the Safety and Efficacy of Oral Encapsulated Microbiota Transplantation Therapy in Peanut Allergic NCT05695261	Rima Rachid	Phase 2
Unknown	Development of Peanut, Sesame, and Tree Nut Allergy in Polish Children at High Risk of Food Allergy NCT05662800	Medical University of Warsaw	—
Active Not Recruiting	A Safety and Efficacy Study of PVX108 in Children and Adolescents With Peanut Allergy NCT05621317	Aravax Pty Ltd	Phase 2
Recruiting	Using Commonly Available Food Products To Treat Food Allergy NCT05503446	University of Southampton	N/A
Active Not Recruiting	Phase I Trial to Evaluate VLP Peanut in Healthy and Peanut Allergic Subjects NCT05476497	Allergy Therapeutics	Phase 1
Recruiting	Immune-supportive Diet and Gut Permeability in Allergic Children NCT05667610	Onze Lieve Vrouwe Gasthuis	N/A
Active Not Recruiting	Peanut Sublingual Immunotherapy (SLIT)-Tablet for Treatment of Peanut Allergy NCT05440643	ALK-Abelló A/S	Phase 1 / Phase 2
Terminated	CNP-201 in Subjects With Peanut Allergy NCT05250856	COUR Pharmaceutical Development Company, Inc.	Phase 1
Completed	Adjuvant Treatment With Abatacept to Promote Remission During Peanut Oral Immunotherapy NCT04872218	Philippe Bégin	Phase 2
Recruiting	Investigating Modified Protocols of Oral Immunotherapy to Validate Efficacy and Safety NCT06256146	McGill University Health Centre/Research Institute of the McGill University Health Centre	N/A
Unknown	Induction of Sustained Unresponsiveness to Peanuts Using High- and Low-dose Peanut Oral Immunotherapy NCT05163574	Medical University of Warsaw	N/A
Completed	Pinpoint Trial: Prebiotics IN Peanut Oral ImmunoTherapy NCT05138757	University of Chicago	Phase 1 / Phase 2
Unknown	A Randomized, Controlled Trial of Probiotic and Peanut Oral Immunotherapy (PPOIT) in Inducing Tolerance in Hon NCT05165329	Chinese University of Hong Kong	N/A
Withdrawn	STEP-IT-UP - Peanut Allergy Study for Infants NCT04761835	Johns Hopkins University	Phase 2
Terminated	Evaluate the Safety, Tolerability, Pharmacodynamics, and Efficacy of CNP-201 in Subjects Ages 16-35 With Peanu NCT04950504	COUR Pharmaceutical Development Company, Inc.	Phase 1
Completed	OMEGA Study: A Study of the Safety and Feasibility of Up-titration With INT301 in Adults With Sensitivity to P NCT04603300	Intrommune Therapeutics	Phase 1
Completed	High and Low Dose Oral Peanut Immunotherapy - Comparison of Efficacy and Safety NCT04415593	Medical University of Warsaw	N/A
Active Not Recruiting	Oral Immunotherapy for Young Children With Peanut Allergy - Small Children OIT NCT04511494	Karolinska Institutet	N/A
Active Not Recruiting	Food Oral Immunotherapy for Peanut Allergy NCT04222491	Massachusetts General Hospital	—
Recruiting	Oral Immunotherapy for Peanut Allergic Patients NCT04163562	InnoUp Farma S.L.	Phase 1 / Phase 2
Completed	Clinical Study Using Biologics to Improve Multi OIT Outcomes (COMBINE) NCT03679676	Stanford University	Phase 2
Terminated	Validation of the HYPONUT Product NCT03849079	University Hospital, Montpellier	N/A
Unknown	Allergology: Information, Data and Knowledge Organization NCT04887441	University Hospital, Montpellier	—
Completed	Immune Basis and Clinical Implications of Threshold-based Phenotypes of Peanut Allergy NCT03907397	Scott Sicherer	Phase 2
Completed	Omalizumab as Monotherapy and as Adjunct Therapy to Multi-Allergen OIT in Food Allergic Participants NCT03881696	National Institute of Allergy and Infectious Diseases (NIAID)	Phase 3
Unknown	VE416 for Treatment of Food Allergy NCT03936998	Massachusetts General Hospital	Phase 1 / Phase 2
Terminated	Pilot Study on Immunotherapy for the Treatment of Persistant Peanut Allergy NCT04974970	University Hospital, Geneva	Phase 1 / Phase 2
Completed	A Study to Evaluate Safety, Tolerability and Immune Response in Adolescents Allergic to Peanut After Receiving NCT03755713	Astellas Pharma Global Development, Inc.	Phase 1
Completed	Study to Evaluate Dupilumab Monotherapy in Pediatric Patients With Peanut Allergy NCT03793608	Regeneron Pharmaceuticals	Phase 2
Completed	Peanut Oral Immunotherapy Study of Early Intervention for Desensitization NCT03736447	Aimmune Therapeutics, Inc.	Phase 3
Completed	Follow-up of the EPITOPE Study to Evaluate Long-term Efficacy and Safety of DBV712 in Young Children NCT03859700	DBV Technologies	Phase 3
Terminated	Real World, Open Label, QOL Assessment of Peanut Immunotherapy AR101 in Children and Adolescents NCT03703791	Aimmune Therapeutics, Inc.	Phase 3
Completed	The Grown Up Peanut Immunotherapy Study NCT03648320	Guy's and St Thomas' NHS Foundation Trust	N/A
Completed	Reactive Doses and Times During Oral Food Challenge to Peanut NCT03852342	University Hospital, Montpellier	—
Completed	Study in Pediatric Subjects With Peanut Allergy to Evaluate Efficacy and Safety of Dupilumab as Adjunct to AR1 NCT03682770	Regeneron Pharmaceuticals	Phase 2
Unknown	Oral Low Doses Tolerance INduction Study for Peanuts NCT04881773	University Hospital, Montpellier	—
Completed	Follow up of LEAP Participants and Their Families NCT03546413	National Institute of Allergy and Infectious Diseases (NIAID)	—
Terminated	Study to Assess Tolerance of Traces in Peanut/Tree Nut Allergic Children. NCT03680066	University Hospital, Geneva	N/A
Active Not Recruiting	Peanut and Tree Nut Desensitization NCT03532360	McGill University Health Centre/Research Institute of the McGill University Health Centre	N/A
Completed	Salvage Peanut Oral Immunotherapy Study NCT03251508	University of North Carolina, Chapel Hill	Phase 1 / Phase 2
Completed	A Study to Assess the Biological Potency of Peanut Allergen Extract in Adolescent and Adult Peanut Allergic Su NCT03352726	DBV Technologies	Phase 1
Completed	Longer-term Study of AR101 in Subjects Who Participated in a Prior AR101 Study (ARC008) NCT03292484	Aimmune Therapeutics, Inc.	Phase 3
Completed	AR101 Real-World Open-Label Extension Study NCT03337542	Aimmune Therapeutics, Inc.	Phase 3
Completed	Safety and Efficacy Study of Viaskin Peanut in Peanut-allergic Young Children 1-3 Years of Age NCT03211247	DBV Technologies	Phase 3
Completed	ARTEMIS Peanut Allergy In Children NCT03201003	Aimmune Therapeutics, Inc.	Phase 3
Completed	Real-World AR101 Market-Supporting Experience Study in Peanut-Allergic Children (RAMSES) NCT03126227	Aimmune Therapeutics, Inc.	Phase 3
Completed	Evaluating the Safety and Efficacy of Oral Encapsulated Fecal Microbiota Transplant in Peanut Allergic Patient NCT02960074	Rima Rachid	Phase 1
Completed	Study to Investigate Etokimab (ANB020) Activity in Adult Participants With Peanut Allergy NCT02920021	AnaptysBio, Inc.	Phase 2
Unknown	Follow-up of the PEPITES Study to Evaluate Long-term Efficacy and Safety of Viaskin Peanut in Children NCT03013517	DBV Technologies	Phase 3
Completed	Allergy Experience Study NCT03513965	Stanford University	N/A
Completed	PALISADE Follow-on Study (ARC004) NCT02993107	Aimmune Therapeutics, Inc.	Phase 3
Completed	A Study to Evaluate Safety, Tolerability and Immune Response in Adults Allergic to Peanut After Receiving Intr NCT02851277	Astellas Pharma Global Development, Inc.	Phase 1
Completed	HAL-MPE1 Safety and Tolerability Study NCT02991885	HAL Allergy	Phase 1
Completed	Early Peanut Introduction: Translation to Clinical Practice NCT03019328	Johns Hopkins University	—
Completed	Safety Study of Viaskin Peanut to Treat Peanut Allergy NCT02916446	DBV Technologies	Phase 3
Unknown	Identification of Anaphylactogenic Antibodies in Peanut Allergy NCT02821286	University of Zurich	—
Completed	Peanut Allergy Oral Immunotherapy Study of AR101 for Desensitization in Children and Adults (PALISADE) NCT02635776	Aimmune Therapeutics, Inc.	Phase 3
Completed	High Threshold Peanut Challenge Study NCT02698033	Massachusetts General Hospital	—
Completed	Visual Recognition of Allergens by Allergic Patients and/or Their Parents NCT02966938	Lille Catholic University	—
Completed	Efficacy and Safety of Viaskin Peanut in Children With Immunoglobulin E (IgE)-Mediated Peanut Allergy NCT02636699	DBV Technologies	Phase 3
Completed	Clinical and Biological Efficacy of Peanut Oral Immunotherapy NCT02979600	Lille Catholic University	—
Completed	Reduction of Peanut Reactivity and Immune Modulation With Anti-IgE Therapy NCT02194530	Weill Medical College of Cornell University	—
Completed	FARE Peanut SLIT and Early Tolerance Induction NCT02304991	University of North Carolina, Chapel Hill	Phase 2
Completed	Oral Desensitization to Peanut in Peanut Allergic Children and Adults Using CPNA Peanut OIT Safety Follow-On S NCT02198664	Aimmune Therapeutics, Inc.	Phase 2
Completed	HAL-MPE1 First-in-human NCT02163018	HAL Allergy	Phase 1
Completed	The Peanut Oral Immunotherapy Study: Safety, Efficacy and Discovery NCT02103270	Stanford University	Phase 2
Completed	Oral Desensitization to Peanut in Peanut-Allergic Children and Adults Using Characterized Peanut Allergen OIT NCT01987817	Aimmune Therapeutics, Inc.	Phase 2
Withdrawn	Walnut Oral Immunotherapy for Tree Nut Allergy NCT01918657	Jonathan Spergel	N/A
Completed	Evaluating Peanut Immunotherapy Dissolving Film in Healthy Subjects NCT03070561	Johns Hopkins University	EARLY_Phase 1
Unknown	Treatment of Severe Peanut Allergy With Xolair (Omalizumab) and Oral Immunotherapy NCT02402231	Caroline Nilsson	Phase 2
Completed	Follow-up of the VIPES Study to Evaluate Efficacy and Safety of Viaskin Peanut in Adults and Children NCT01955109	DBV Technologies	Phase 2
Completed	The Utility of Food-Specific IgE Measured With the IMMULITE 2000 Assay to Predict Symptomatic Food Allergy NCT01950533	National Jewish Health	—
Completed	Tolerance Following Peanut Oral Immunotherapy NCT01750879	Massachusetts General Hospital	Phase 1 / Phase 2
Unknown	Peanut Oral Induction Tolerance in Peanut's Allergic Teenagers NCT02046083	University Hospital, Clermont-Ferrand	Phase 2 / Phase 3
Unknown	Canadian Peanut Thresholds Study NCT01812798	McMaster University	N/A
Completed	Peanut Reactivity Reduced by Oral Tolerance in an Anti-IgE Clinical Trial NCT01781637	Boston Children's Hospital	Phase 1 / Phase 2
Terminated	The Safety and Efficacy of a Peanut Immunotherapy Dissolving Film for Peanut Allergy NCT01897077	Johns Hopkins University	Phase 1 / Phase 2
Completed	Efficacy and Safety of Several Doses of Viaskin Peanut in Adults and Children With Peanut Allergy NCT01675882	DBV Technologies	Phase 2
Completed	Peanut Allergy Oral Immunotherapy Desensitization NCT01601522	Hamilton Health Sciences Corporation	Phase 2
Completed	Evaluation of Allergenicity of Hypoallergenic Peanut Product in Peanut Allergic Subjects NCT01489514	University of North Carolina, Chapel Hill	—
Completed	Sublingual Immunotherapy for Peanut Allergy and Induction of Tolerance NCT01373242	University of North Carolina, Chapel Hill	Phase 1 / Phase 2
Completed	Oral Peanut Immunotherapy NCT01324401	Massachusetts General Hospital	N/A
Completed	Xolair Enhances Oral Desensitization in Peanut Allergic Patients NCT01290913	Lynda Schneider	Phase 1 / Phase 2
Terminated	Peanut Oral Immunotherapy (OIT) - Initial Pilot Study in Adults NCT01274429	University of North Carolina, Chapel Hill	Phase 1 / Phase 2
Completed	Epicutaneous Immunotherapy in Peanut Allergy in Children NCT01197053	Assistance Publique - Hôpitaux de Paris	Phase 2
Completed	Safety of Epicutaneous Immunotherapy for the Treatment of Peanut Allergy NCT01170286	DBV Technologies	Phase 1
Completed	Understanding How the Immune System Responds to Viruses in Peanut Allergic Children Undergoing Peanut Oral Imm NCT01074840	University of Texas Southwestern Medical Center	N/A
Completed	Omalizumab in the Treatment of Peanut Allergy NCT00949078	Johns Hopkins University	Phase 2
Completed	Study of Tolerance to Oral Peanut NCT01259804	Cambridge University Hospitals NHS Foundation Trust	Phase 1
No Longer Available	Viaskin® Peanut (DBV712) Expanded Access Protocol NCT04371627	DBV Technologies	—
Available	Expanded Access Protocol of Viaskin® Peanut (DBV712) in Peanut-allergic Children NCT05424731	DBV Technologies	—
Withdrawn	Efficacy and Safety of 4 Doses of QGE031 in Patients 18-50 Years of Age With Peanut Allergy NCT01451450	Novartis Pharmaceuticals	Phase 2